Study wrapper · #1074
Protecting Musculoskeletal Development and Physical Function in Adolescents on GLP-1 Therapy.
Smith WA, Kim A, Khalil TJ, et al. Childhood obesity. 2026.
DOI: 10.1177/21532176261475103PubMed: 42544560
Editor's note
A commentary rather than primary data, this paper raises a plausible concern that GLP-1-associated weight loss in adolescents could attenuate peak muscle and bone accrual. The authors acknowledge longitudinal pediatric evidence is limited, so the musculoskeletal caution is precautionary rather than established. Semaglutide is central to the discussion but the piece offers guidance, not new outcome data.
Plain-language abstract
This perspective piece considers how GLP-1 medications such as semaglutide, used for adolescent obesity, may affect muscle and bone development during growth. The authors argue for pairing these medications with resistance training and adequate protein to preserve lean mass.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026